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a b s t r a c t
Poliomavirus JC replicates in glial cells in the brain, and causes the fatal demyelinating disease,
progressive multifocal leukoencephalopathy (PML). PML is usually seen in patients with underlying
immunocompromised conditions, notably among AIDS patients and those on chronic immunosuppres-
sive regimens. The late leader sequence of JC virus contains an open reading frame encoding a small
regulatory protein called agnoprotein. Agnoprotein contributes to progressive viral infection by playing
signiﬁcant roles in viral replication cycle. Here, we demonstrate that agnoprotein can be detected in cell-
free fractions of glial cultures infected with JCV, transfected with expression plasmids or transduced with
an adenovirus expression system. We also provide evidence that extracellular agnoprotein can be taken
up by uninfected neighboring cells. These studies have revealed a novel phenomenon of agnoprotein
during the viral life cycle with a potential of developing diagnostic and therapeutic interventions.
& 2014 Elsevier Inc. All rights reserved.
Introduction
JC virus (JCV) is a human polyomavirus that infects greater than
50% of the human population during childhood, and establishes a
latent/persistent infection for the rest of the life in healthy
individuals (Weber, 2008; Moens and Johannessen, 2008). Repli-
cation of the neurotropic strain of JCV in glial cells causes the fatal
demyelinating disease of the central nervous system, progressive
multifocal leukoencephalopathy (PML), which is seen in patients
with underlying immunocompromised conditions, notably HIV-1/
AIDS (Safak et al., 2005; Berger and Concha, 1995; Miller et al.,
1982). PML is the only viral demyelinating disease of the human
brain characterized by lytic infection of oligodendrocytes (Safak
et al., 2005; Berger and Concha, 1995; Padgett et al., 1971). Over
the past few years, exogenous immunosuppressive treatments
such as natalizumab, efalizumab, and rituximab have also been
associated with PML in patients with autoimmune diseases,
including Multiple Sclerosis, Crohn's Disease, Psoriasis, and Lupus
(Ferenczy et al., 2012; Tavazzi et al., 2011). Like other polyoma-
viruses, the genome of JCV is composed of a double-stranded
circular DNA genome of approximately 5 kb in size with a bi-
directional non-coding control region that is located between the
early and late coding sequences (Ferenczy et al., 2012). The early
coding region is responsible for the expression of large T antigen (T-
Ag), small t antigen (t-Ag), and a group of T0 proteins, which are
produced upon alternative splicing of the early primary transcript.
Similarly, alternative splicing of the late transcript results in
production of the viral capsid proteins VP1, VP2, and VP3 which
are essential for completion of the viral lytic cycle and formation of
viral particles.
In addition to the capsid proteins, JCV encodes a small (71 aa
long), regulatory, phosphoprotein, agnoprotein, from the late viral
transcript. Agnoprotein forms highly stable dimers and oligomers
(Saribas et al., 2011, 2013) and has an important role in viral DNA
replication by enhancing T-Ag binding to the origin of replication
(Saribas et al., 2012). The expression pattern of agnoprotein in
tissue sections from PML shows localization to the cytoplasmic
and perinuclear regions of infected glial cells (Okada et al., 2002).
Recent observations also suggest that agnoprotein localizes to the
endoplasmic reticulum, interacts with lipid membranes and may
function as a viroporin (Suzuki et al., 2010, 2013). Furthermore,
agnoprotein expression is required for the successful completion
of JC virus life cycle, because mutant JC virus with a deletion in the
agno gene is unable to propagate (Ellis et al., 2013, Sariyer et al.,
2006, 2011a).
Because of its highly basic structure, co-localization with endo-
plasmic reticulum at the perinuclear area and its association with
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intracellular lipid membranes, we sought to investigate possible
release of agnoprotein by infected cells. Our results have revealed
the presence of extracellular agnoprotein in cell free supernatant
fractions of infected cultures as well as in glial cell lines expressing
agnoprotein in the absence of viral lytic infection.
Results
To determine the possible secretion of JC virus agnoprotein
from infected cells, we ﬁrst infected SVG-A human glial cell line
with Mad-1 strain of JC virus. SVG-A cells were transfected with
viral genome to initiate a uniform infection cycle and whole cell
protein lysates were collected at 24 h intervals up to 10 days post-
infection (dpi). Protein samples were processed for SDS-PAGE,
transferred to nitrocellulose membranes and expression of VP1
and agnoprotein were determined by Western blot. As shown in
Fig. 1A and B, VP1 expression was started at the second day post-
infections, reached a peak at 4 dpi, and showed a dramatic
decrease at 6 and 7 dpi that corresponded to the time of the
completion of the ﬁrst replication cycle (Sariyer et al., 2009).
Similar to the VP1, agnoprotein expression was detectable as early
as 2 dpi, reached a peak at 4 dpi, and stayed high until 6 dpi.
Consistent with the expression of VP1, agnoprotein levels were
barely detectable at 6 and 7 dpi. Interestingly, agnoprotein expres-
sion levels came back to peak levels at 9 dpi, followed by another
sharp reduction in expression at 10 dpi. These experiments
suggested that unlike the VP1 expression, agnoprotein showed a
dynamic expression pattern during the replication cycle of the
virus in glial cells. Next, we asked whether agnoprotein could be
released by infected cells and its expression in the cells correlate
with its release pattern during the course of viral replication cycle.
The growth media from the cells were collected from the same
infection studies presented in Fig. 1A, and processed for agnopro-
tein detection by immunoprecipitation followed by Western blot.
Whole cell protein lysates from 9 dpi and 0 dpi (uninfected) were
loaded as positive and negative controls of agnoprotein expres-
sion. As shown in Fig. 1C (upper panel), unlike to its cellular
expression, agnoprotein was not detected in growth media earlier
than 4 dpi (compare Fig. 1A and C). Surprisingly, a signiﬁcant
amount of agnoprotein was present in the growth media at 4 dpi
when there were still peak levels of cellular expression (compare
Fig. 1A lane 5 with C lane 6). At 6 and 7 dpi when agnoprotein
cellular expression levels started to decrease, agnoprotein was still
present in the growth media in signiﬁcant amounts (compare
Fig. 1A lanes 7 and 8 withC lanes 8 and 9). Interestingly, there were
no detectable agnoprotein in growth media at 8 dpi when agno-
protein expression began to reappear in the cells. Agnoprotein was
again present in the growth media in parallel to its peak expres-
sion at 9 dpi and stayed at a constant level in contrast to a drop in
its cellular expression level at 10 dpi. To determine the time of
viral release, the major capcid protein VP1 was also immunopre-
cipitated from the growth media of infected cells and analyzed by
Western blotting (Fig. 1C lower panel). Unlike agnoprotein, VP1
Fig. 1. Agnoprotein is detected in cell-free fractions of glial cells infected with JCV. A. SVG-A cells were transfected/infected with Mad-1 JCV as described previously (Sariyer
and Khalili, 2011b; Uleri et al., 2013). Whole cell protein samples were prepared from cellular pellets with 24 h intervals up to 10 dpi. Expression of VP1 and agnoprotein
were analyzed by Western blot. In lane 1, protein samples from uninfected SVG-A cells were loaded as negative control (0 dpi). Membranes were stripped and re-probed for
β-tubulin as a loading control. dpi is an abbreviation for “days post-infection”. B. Bar graph representation of normalized expression of VP1 and agnoprotein during JCV
infection in glial cells. C. Immunoprecipitation of agnoprotein and VP1 from the growth medium of cells infected with JC virus. Immune complexes were separated by SDS-
PAGE and processed for Western blot of agnoprotein and VP1. In lanes 1 and 2, whole-cell protein lysates from JCV-infected SVG-A cells (9 dpi) and from uninfected cells
(0 dpi) were loaded as positive and negative controls of agnoprotein and VP1 expression, respectively. D. Q-PCR analysis of JCV copy number in growth medium. The growth
medium of JCV-infected cells used in IP studies (panel C) were also subjected to Q-PCR analysis for the detection of viral loads as described in Materials and Methods. All
experiments were carried out in triplicate. Images depict representative data.
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appeared in the growth media at 6 and 7 dpi when its cellular
expression levels was dropping (compare Fig. 1A and C), and
showed a lower but constant level at 8–10 dpi. In addition, Q-PCR
analysis of the viral copy numbers in the growth medium further
demonstrated that most viral particles were released at 6 and
7 dpi (Fig. 1D). Thus, these infection studies have revealed the
presence of extracellular agnoprotein which was released into the
growth media by infected cells before the completion of viral lytic
life cycle.
One can argue that the presence of viral regulatory proteins
in the growth medium of infected cultures could be due to the
mechanical disruption of the cell membrane by the viral particles
at the stage of their release from infected cells. In order to
investigate this possibility, agnoprotein was cloned into a mam-
malian expression vector pSELECT-GFPzeo (InvivoGen, USA). The
ﬁnal plasmid construct contained two transcription units, the ﬁrst
drove the expression of agnoprotein and the second drove the
expression of GFP as described by the manufacturer. T98G glio-
blastoma cell lines were transfected with this construct and
growth medium was collected in parallel to the whole cell protein
lysates at 48 h post-transfection. As shown in Fig. 2A, agnoprotein
was clearly detected in growth media as well as in whole cell
protein lysates (lane 6 and 3, respectively). In parallel to the
agnoprotein, GFP was also immunoprecipitated from the same
set of experiments. Unlike agnoprotein, GFP was not detected in
growth media of the cells expressing either GFP together with
agnoprotein (Fig. 2B, lane 6) or GFP alone from control plasmid
transfections (Fig. 2B, lane 5). Of note, GFP was sufﬁciently
immunoprecipitated by the anti-GFP antibody from whole cell
protein lysates suggesting its efﬁciency for IP studies (Fig. 2B, lanes
7-9). The possible toxicity of agnoprotein expression for the cells
was also assessed by live-ﬂuorescein imaging of GFP (Fig. 2C) and
MTT viability (Fig. 2D) assays, and found no signiﬁcant effect on
cellular morphology and viability, respectively. Since both agno-
protein and GFP were expressed from the same plasmid backbone,
detection of extracellular agnoprotein with no GFP contamination
suggested that agnoprotein was possibly secreted by glial cells. In
order to investigate this possibility, agnoprotein was cloned into a
mammalian expression vector pCGT7 as a fusion protein to T7-tag.
The 11 amino acid T7-tag allowed us to utilize a commercially
available monoclonal anti-T7 antibody for the detection of agno-
protein. T98G glioblastoma cell lines were transfected with this
construct and growth medium was collected in parallel to whole
cell protein lysates at 12, 24, 48, and 72 h post-transfections. As
shown in Fig. 3A, agnoprotein expression started at 12 h, reached
the highest level at 24 h and gradually decreased at 48 and 72 h
post-transfections in the cellular lysates (lanes 1–5). In parallel,
immunoprecipitation of agnoprotein from the growth media was
performed at the same time points. Interestingly, agnoprotein
appeared in the growth medium at 24 h and the signal was
Fig. 2. Agnoprotein is released by glial cells. A. Immunoprecipitation of agnoprotein in growth media. T98G cells were transfected with pSELECT-GFPzeo control plasmid
encoding GFP or with pSELECT-GFPzeo-agno expression plasmid which contained two transcription units, the ﬁrst drove the expression of agnoprotein and the second drove
the expression of GFP. Growth medium was collected at 48 h post-transfections simultaneously along with the whole cell protein extracts. Agnoprotein was
immunoprecipitated in the growth medium, and analyzed by Western blotting (lanes 4-6).Whole cell protein extracts were also processed and loaded in parallel for the
cellular expression of agnoprotein (lanes 1-3).Ab-Lc points the light chain of agnoprotein antibody. B. Immunoprecipitation of GFP in growth medium of T98G cells. GFP was
immunoprecipitated in the growth media from the same set of experiments presented in panel A and analyzed by Western blot (lanes 4-6).Whole cell protein extracts were
also processed and loaded in parallel for the cellular expression of GFP (lanes 1-3).Efﬁciency of anti-GFP antibody for immunoprecipitating GFP protein was also assessed in
whole cell protein lysates and shown (right panel, lanes 7–9). Ab-Hc indicates the IgG heavy chain of the antibody. C. T98G cells were transfected with expression plasmids
encoding either GFP alone or GFP and agnoprotein together as described above. Live-ﬂuorescein images of GFP expression was taken at 48 h posttransfections. Transfection
efﬁciencies were determined as 40% for GFP control and 43% for GFPþagnoprotein by calculating the percentile of GFP positive cells over total number of cells. D. T98G
cells were transfected with expression plasmids encoding either GFP alone or GFP and agnoprotein together as described in panel A and B. Forty eight hours post-
transfections, MTT activities were detected. MTT activity of untransfected cells is presented as 100%, and MTT activity of the transfected groups is presented proportionally.
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decreased in correlation with its expression pattern in the cells
(Fig. 3A, lanes 6–10). These data, once again, suggested that
agnoprotein may be released into the extracellular matrix in the
absence of viral lytic infection. One possible mechanism for
agnoprotein release could be the involvement of exosomes. To
clarify whether exosomes were involved in agnoprotein release,
T98G cells were transfected with pCGT7-Agno expression plasmid
and conditioned media was collected at 24 h post-transfections.
Exosomes were precipitated using ExoQuick exosome precipita-
tion solution (System Biosciences, CA, USA) according to the
manufacturer's instructions, and lysed with TNN buffer containing
1% NP40. As shown in Fig. 3B, exosome lysates from cells expres-
sing agnoprotein contained Hsp70 (bottom panel, lanes 3 and 4), a
well described internal exosome marker (Lancaster and Febbraio,
2005) with no detectable levels of agnoprotein (top panel, lane 4).
In addition, agnoprotein was clearly detected by immunoprecipi-
tation in exosome-depleted growth media (top panel, lane 6)
suggesting that extracellular agnoprotein may not be associated
with exosomes. Many secretory proteins are secreted from cells by
using the endoplasmic reticulum to Golgi pathway (conventional
secretion pathway), which can be blocked by Brefeldin-A (BFA). To
determine the possible role of ER to Golgi transport in agnoprotein
release, T98G cells were transfected with pCGT7-agno expression
plasmid, and growth medium of the cells was changed with fresh
media containing BFA or Monensin at 24 h post-transfection.
Whole cell protein lysates were prepared at 24 h (no treatment),
Fig. 3. Agnoprotein release may involve conventional pathway. A. Immunoprecipitation of agnoprotein in growth media from T98-G cells. Cells were transfected with an
expression polasmid encoding T7-tagged agnoprotein (pCGT7-Agno) and growth media was collected at 0, 12, 24, 48, and 72 h post-transfections simultaneously along with
whole cell extracts. Agnoprotein was immunoprecipitated from the growth media, and analyzed by Western blotting (lanes 6–10). Whole cell protein extracts were also
processed and loaded in parallel for the cellular expression of agnoprotein (lanes 1–5). Ab-Lc points the light chain of T7 tag antibody. B. The secreted agnoprotein is not
associated with extracellular vesicles. Extracellular vesicles were isolated from growth media of either control cells or cells expressing agnoprotein by ExoQuick exosome
precipitation solution (System Biosciences, SBI) according to the manufacturer's instructions. The precipitated exosomes were lysed with TNN buffer containing 1% NP40, and
analyzed by Western blot for the detection of agnoprotein (upper panel, lanes 3 and 4) and Hsp70 (bottom panel, lanes 3 and 4) proteins. The exosome depleted growth
media was subjected to immunoprecipitation for agnoprotein (lanes 5 and 6) by using an anti-T7 tag monoclonal antibody. Whole cell protein extracts were also processed in
parallel for the cellular expression of agnoprotein (lanes 1 and 2). C. Agnoprotein secretion is suppressed by Brefeldin A. T98G cells were transfected with pCGT7-Agno
expression plasmid and grouped as 24 h, þ1 h, and þ2 h. At 24 h post-transfection, growth media and whole cell protein extracts were obtained from the ﬁrst 24 h group for
the cellular and secreted expression of agnoprotein. Meanwhile, the growth media of þ1 h and þ2 h groups were aspirated, cells were washed twice with PBS, and treated
with Brefeldin A (10 μg/ml) or Monensin (1 μM) in fresh growth media. At 1 h and 2 h post-treatment, growth mediumwas collected and processed for immunoprecipitation
of agnoprotein (lower panel). In parallel, whole cell protein extracts were also prepared and analyzed by Western blot for its cellular expression (top panel). Bar graph
represents the relative expression of agnoprotein in whole cell lysates and growth medium presented in the upper panels. All experiments were carried out in triplicate.
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24þ1 h, and 24þ2 h post-treatment. In parallel, growth medium
from cells was collected at the same time points and processed for
immunoprecipitation for agnoprotein. As shown in Fig. 3C, agno-
protein was readily detectable in the growth medium at 24 h post-
transfections (lanes 2, 6, and 10). As expected, the level of
extracellular agnoprotein was reduced at 24þ1 h in control, BFA,
and Monensin treatments (lanes, 3, 7, and 11). Interestingly, only
BFA but not Monensin caused a signiﬁcant reduction in the levels
of extracellular agnoprotein at 24þ2 h post-treatments (compare
lane 8 with lane 4 and 12), suggesting possible involvement of ER
to Golgi transport pathway in agnoprotein release into the
extracellular space.
In an alternative approach, agnoprotein release was also
analyzed by adenoviral transduction (Fig. 4A). Tc620 oligodendro-
glioma cells were transduced with aneno-null and adeno-agno
constructs and whole cell protein lysates and growth media were
collected at 48 h post-transduction. Consistent with the infection
and transfection studies, agnoprotein was once again detected in
the cell-free supernatants of cells transduced with adeno-agno
construct (Fig. 3A, lane 4). Next, we asked whether secreted
agnoprotein could be taken up by glial cells. First, we collected
growth media and whole cell protein lysates from Tc620 cells
either transduced with adeno-null or adeno-agnoprotein con-
structs. In the second step of the experiment, another set of
Tc620 cells were only incubated with the conditioned media
collected from control cells and cells transduced with either
adeno-null or adeno-agno (50% of culture volume). At 48 h post-
incubation, cells were washed three times with PBS, and whole
cell protein extracts were prepared. Both direct and indirect
protein extracts were processed for agnoprotein detection by
Western blotting. As expected, agnoprotein was detected in the
whole cell protein lysates (Fig. 3B, lane 3). Interestingly, a decent
amount of agnoprotein was also detected in extracts prepared
from cells treated with conditioned media from adeno-agno
transduced cells (Fig. 4B, lane 6), suggesting that extracellular
agnoprotein in the conditioned media was possibly taken up by
the second set of Tc620 cells. We also analyzed the cellular uptake
and subcellular localization of agnoprotein by immunocytochem-
istry. We treated TC620 cells with conditioned media from cells
either transduced with adeno-agno (CM-Agno) or adeno-null
(CM-control). Cells were ﬁxed at various time points and pro-
cessed for immunostaining as described in Materials and Methods.
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Fig. 4. Agnoprotein is taken up by glial cells. A. TC620 cells were transduced with either a null adenovirus or adenovirus encoding agnoprotein. Growth medium was
collected in parallel to whole cell protein lysates at 48 h post-transduction. Agnoprotein was immunoprecipitated from growth medium and analyzed by Western blot (lanes
3 and 4) as described in Fig. 1C. Whole cell protein lysates were also loaded as positive and negative controls of expression (lanes 1 and 2, respectively). B. Western blot
analysis of whole cell extracts from cells expressing agnoprotein (lanes 1–3) or from cells treated with conditioned medium obtained from control, adeno-null, and adeno-
agno transduced cells (lanes 4-6). C. TC620 cells were seeded in two-well chamber slides and treated with growth medium from agnoprotein-expressing cells or control cells.
At 3, 9, and 24 h post-treatment, cells were washed 3 with PBS and ﬁxed with cold acetone/methanol (1/1). Immunocytochemistry was performed to detect agnoprotein as
described in Materials and Methods. D. SVGA cells were transfected/infected with Mad-1 JCV and cells were ﬁxed on 2-well chamber slides at 10, 20, and 30 days post-
infection. Expression and co-localization of VP1 and agnoprotein were analyzed by immunocytochemistry. Nuclei were also labeled with DAPI (blue) and merged with the
agno (red) and VP1 (green). Arrows point cells positive for agno (red) and negative for VP1 (green) ﬂuorescein.
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A signal corresponding to the presence of agnoprotein was detected
within the cultured cells as early as 3 h post-treatments (Fig. 3C,
upper panel). At 9 and 24 h post-treatments, the characteristic
cytoplasmic localization of agnoprotein was observed. In the next
set of experiments, we asked whether agnoprotein secreted during
the infection was taken up by neighboring uninfected cells. To
analyze this, SVG-A cells were infected with Mad1 strain of JCV and
cells were ﬁxed at 10, 20, and 30 day post-infection. Immunocyto-
chemical detection of agnoprotein and VP1 was performed by using
a mouse monoclonal antibody to VP1 (Pab597) and a rabbit
polyclonal antibody to agnoprotein (Pab7903). As shown in
Fig. 4D, VP1 showed an exclusive nuclear expression (green) and
agnoprotein (red) showed its characteristic cytoplasmic and peri-
nuclear localization within the infected glial cells. Interestingly,
merge analysis of green (VP1) and red (agnoprotein) ﬂuorescein
channels revealed the presence of agnoprotein positive but VP1
negative cells within the infected SVG-A cultures (depicted by
arrows). Since both VP1 and agnoprotein are expressed from the
late viral transcript, the presence of agnoprotein in neighboring
cells with no detectable VP1 expression may suggest its possible
uptake from the culture medium.
Discussion
Many eukaryotic viruses encode small secretory proteins which
provide essential functions for the replication cycle and the
pathogenesis of the diseases (Lucas and McFadden, 2004). Agno-
protein is a small regulatory protein of JC virus and it is not
incorporated into the virions therefore it should be present in cells
actively replicating the virus. However, our results have revealed
that agnoprotein is also present in cell-free fractions of infected
glial cultures. This detection of agnoprotein in growth medium
was not only due to the lytic destruction of the infected cell
membrane during virion release of viral particles. Analysis of viral
copy numbers and detection of VP1 in growth media suggest that
completion of ﬁrst round of JCV infection cycle starts around 5 dpi.
Detection of agnoprotein in growth media of cells at 4 dpi with no
detectable levels of VP1 protein and viral genome clearly suggest
that agnoprotein secretion may occur prior to virion release.
In addition, detection of agnoprotein in cell-free fractions of
T98G cells transfected with a dual-promoter expression plasmid
encoding agnoprotein and GFP has further conﬁrmed that agno-
protein is indeed released by transfected cells with no detectable
GFP contamination. Moreover, glial cell lines transduced with an
adenovirus encoding agnoprotein also resulted in its release.
The presence of agnoprotein in the extracellular matrix may
suggest an important novel role of agnoprotein in the molecular
pathogenesis of JCV infection in the brain. One possible role for the
secreted agnoprotein could be an extracellular immunomodula-
tory function to facilitate the invasion of the virus within the
infected tissue. Many DNA viruses encode immunomodulatory
proteins that are secreted into the extracellular matrix (Lucas and
McFadden, 2004). Among these, myxomavirus encodes a small 37-
kDa secretory protein (M-T7) which binds to a broad spectrum of
C/CC/CXC chemokines and inhibits leukocyte chemotaxis into
virus-infected tissue (Liu et al., 2000, 2004). Some strains of
vaccinia virus encode vaccinia complement control protein
(VCP), which has been shown to interact with complement
components and limit the complement cascade (Kotwal and
Moss, 1988; Murthy et al., 2001). Whether secreted agnoprotein
has an immunomodulatory function that is similar to the myxoma
and vaccinia virus proteins remains to be determined.
PML is usually a fatal disease and little is known about the
progression of the disease from latency to the pathologic stage of
the disease. Most PML cases are diagnosed at very late stage of
disease progression when neurological symptoms appear and this
increases the morbidity and mortality of the disease. Currently,
PML is diagnosed by combination of JCV DNA detection in
cerebrospinal ﬂuid or brain biopsy specimen and by the observa-
tion of multifocal non-enhancing lesions in MRI. There is no
established diagnostic early marker applicable to the clinic that
indicates reactivation of JCV. Since the agnoprotein is only
expressed by cells actively replicating the virus and released into
the extracellular matrix, detection of agnoprotein in clinical
samples may serve as such a marker. This would be a signiﬁcant
advance in clinical diagnosis. Whether agnoprotein could be a
biomarker for the detection of the early stages of JCV reactivation
and the progression of PML remains to be investigated.
In conclusion, our results suggest that agnoprotein is released
by infected glial cells during the course of viral propagation,
and present in the extracellular matrix. We have also provided
evidence that agnoprotein may also be taken up by neighboring
uninfected cells that may play important roles in the pathogenesis
and progression of the disease, PML. These results open new
possibilities for research to understand the molecular pathogen-
esis of JCV.
Materials and methods
JCV genomic strains, plasmid constructs, and adenovirus vectors
The wild type Mad1 strain of JCV was linearized by BamH1
digestion, and cloned into the pBlueScript KS (þ) vector as
previously described (Sariyer and Khalili, 2011b). The pCGT7-
Agno expression vector was created as following. The full-length
coding region for the agnoprotein was ampliﬁed by using Agno-
forward-(Xba1) 50- attctatctagagttcttcgccagctgtcacgt-30 and Agno-
reverse-(BamH1) 50- attctaggatccctatgtagcttttggttcaggca-30 pri-
mers by using the Mad1 genome as template. The ampliﬁcation
products were subjected to Klenow reaction, and were blunt-end
ligated into pBlueScript KS (þ) vector. The agnoprotein coding
sequence was removed from pBlueScript KS (þ) background by
Xba1/BamH1 digestion and cloned into pCGT7 vector. The ﬁnal
construct was sequenced to conﬁrm the integrity and sequence
frame before using in the experiments. The pSELECT-GFPzeo-agno
expression vector was created as following. The full-length coding
region for the agnoprotein was ampliﬁed by using Agno-forward-
(SalI) 50-accttccagtcgacatggttcttcgccagctgtcacgtaa-30 and Agno-
reverse-(BamH1) 50- attctaggatccctatgtagcttttggttcaggca-30 pri-
mers by using the Mad1 genome as template. The ampliﬁcation
products were subjected to Klenow reaction, and were blunt-end
ligated into pBlueScript KS (þ) vector. The agnoprotein coding
sequence was removed from pBlueScript KS (þ) background by
SalI/BamH1 digestion and cloned into pCGT7 vector. The ﬁnal
construct was sequenced to conﬁrm the integrity and sequence
frame before using in the experiments. Adenovirus construct
expressing JCV agnoprotein (Ad-Agno) was described previously
(Merabova et al, 2008).
JCV infection
Transfection/infection of cells with JCV Mad-1 genome was
described previously (Sariyer and Khalili, 2011b; Uleri et al, 2013).
Brieﬂy, pBlue.script-Mad1-WT plasmid was digested with BamH1
enzyme to remove the complete viral genome from pBlue.Script
KS (þ) plasmid. SVG-A cells were plated in 10 different T75-cm
tissue culture ﬂasks at a conﬂuence of 0.5106 cells per T75-cm
tissue culture ﬂask, and transfected/infected with the Mad1
genomic DNA (10 μg/ﬂask) using Fugene-6 transfection reagent
as indicated by the manufacturer (Roche). For the time course
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analysis of JC virus infection cycle, growth media of the cells and
whole cell protein lysates were collected at 24 h intervals up to 10
days post-infection (dpi). Of note, the growth media of the cells
were never removed from the cells during the course of 10 day
infection. Instead, 5 ml of fresh media was added to the cells at
4 dpi and 8 dpi for the late time points of the infections. Whole cell
protein extracts were prepared to analyze the expression of viral
proteins. The growth media of the cells were also obtained in
parallel to whole cell protein extracts to analyze the presence of
viral proteins (agnoprotein and VP1) by immunoprecipitation and
to measure viral load by Q-PCR analysis.
Immunoprecipitation of agnoprotein from growth media
Growth media of cells expressing agnoprotein was collected at
different time points as indicated in the experimental settings.
Before subjecting to immunoprecipitation, growth media was
centrifuged at 3000 rpm for at least 15 min to remove cellular
debris, and diluted with TNN buffer containing 1% NP-40 at a ratio
of 1:1. Immunoprecipitations were performed with a Dynabeadss
Protein G immunoprecipitation kit (Invitrogen). Since the growth
media of the cells was supplemented with 10% fetal bovine serum
(FBS) which contained massive amount of immunoglobulins, we
followed two steps to avoid the saturation of the beads with FBS
originated immunoglobulins. In the ﬁrst step, we depleted the
immunoglobulins from media by incubating them with protein G
beads. Secondly, anti-agno antibody (#7903) was pre-loaded on
dynabeads before subjecting to immunoprecipitations.
Q-PCR analyses of JCV copy numbers in growth media
Q-PCR analysis of JCV copy numbers in growth media was
performed as described previously (Uleri et al., 2013). Brieﬂy, the
culture medium (containing viral particles) were collected and
incubated at 95 1C for 10 min to inactivate virus. Ten microliters of
the medium was then used as a template in Q-PCR reactions. The
standard curve was obtained after serial dilution of pJCV, a
plasmid containing the whole genome of the JCV Mad-1 strain.
The standard curve was then used to extrapolate the viral load of
each sample. Negative and positive controls were included in each
reaction and each sample was tested in triplicate. All Q-PCR
analyses were done by using Light cycler 480 (Roche). Primers
were JCV Q-PCR-forward: 50-AGTTGATGGGCAGCCTATGTA-30 and
JCV Q-PCR-reverse: 50- TCATGTCTGGGTCCCCTGGA-30. The probe
for the Q-PCR was 50-/5HEX/CATGGA TGCTCAAGTAGAGGAGGTTA-
GAGTTT/3BHQ_1/-30.
Exosome puriﬁcation
Extracellular vesicles were isolated from growth media of
either control cells or cells expressing agnoprotein by ExoQuick
exosome precipitation solution (System Biosciences, SBI) accord-
ing to the manufacturer's instructions. Brieﬂy, 2 ml ExoQuick
exosome precipitation solution was mixed with 10 ml growth
media from cells expressing agnoprotein and incubated at 4 1C
for 12 h (overnight). The mixture was centrifuged and exosomes
were precipitated at 1500g for 30 min. The supernatant (exosome
depleted media) was recovered and all the trace of ﬂuid was
removed. The precipitated exosomes were lysed with TNN buffer
containing 1% NP40, and analyzed by Western blot for the
detection of agnoprotein and exosome marker Hsp70 (Santa Cruz,
W27). The exosome depleted growth media was subjected to
immunoprecipitation for agnoprotein. Whole-cell protein extracts
were also processed in parallel for the cellular expression of
agnoprotein.
Brefeldin A and Monensin treatments
T98G cells were plated in 60 mm tissue culture dishes at a
density of 80%, and transfected with pCGT7-Agno expression
plasmid. At 24 h post-transfections, cells were washed 3 with
PBS and fresh growth media were added with BFA or Monensin.
The growth media of the cells were collected at þ1 h and þ2 h of
the 24 h post-transfection. In parallel, whole cell protein lysates
were also prepared to analyze the cellular and released agnopro-
tein ratios. Whole cell protein extracts were processed for Western
blotting using an anti-T7 monoclonal antibody. In parallel, agno-
protein was immunoprecipitated from growth media with
Dynabeadss Protein G immunoprecipitation kit (Invitrogen #
10007D) as described above.
Immunocytochemistry
In order to show cellular uptake of agnoprotein, Tc620 cells
were seeded in two-well chamber slides and treated with condi-
tioned media obtained from agnoprotein expressing cells. At 3, 9,
and 24 h post-treatments, cells were washed 3 with PBS, and
ﬁxed with cold acetone/methanol (1/1). Slides were blocked with a
10% BSA solution, followed by incubation with anti-agno (7903)
polyclonal antibody. Cells were then incubated with FITC-
conjugated secondary antibody, mounted with aqueous mounting
medium, and examined under immunoﬂourescence microscope.
To analyze the expression of agnoprotein in infected cells, SVG-A
cells were infected with JC virus and ﬁxed with cold acetone/
methanol (1/1) at 10, 20, and 30 day postinfections (dpi). After
treatment with a 10% BSA solution, samples were incubated with
JCV VP1-speciﬁc monoclonal and anti-agno (7903) polyclonal
antibodies followed by incubation with FITC and Rhodamine-
conjugated secondary antibodies. Samples were mounted with
aqueous mounting media with DAPI, and examined under ﬂuor-
escein microscope.
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